TrialAnnals of oncology : official journal of the European Society for Medical Oncology2013

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

S F Slovin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.